Why the study?
Appropriate weaning is crucial for critically ill patients requiring respiratory support, but a remarkable proportion of them are difficult to wean.
Does levosimendan facilitate weaning from cardiorespiratory support in critically ill patients?
Does levosimendan facilitate weaning from cardiorespiratory support in critically ill patients?
This position paper outlines expert consensus on the use of levosimendan to facilitate weaning from cardiorespiratory support in critically ill patients.
Answers are grounded in this paper and cite their sources.
Supports levosimendan for weaning from cardiorespiratory support in critically ill patients; extends evidence with expert consensus guidance.
Appropriate weaning is of crucial importance for critically ill patients requiring respiratory support. However, a remarkable proportion of them are difficult to wean. Levosimendan is a positive inotropic agent characterized by vasodilatory properties, which is used for the treatment of acute decompensated heart failure or in patients needing inotropic treatment, including cardiogenic shock, septic shock, pulmonary hypertension and right ventricular dysfunction, needed for hemodynamic support in patients with diuretic resistance, and weaning either from ventilator or from extracorporeal membrane oxygenation. This position paper will discuss the use of levosimendan in facilitating weaning from cardiorespiratory support in critically ill patients, according to available evidence and the personal experience of a group of Italian Experts.
No takes yet. Share an insight, caveat, or question.
Sangalli et al. (2020) conducted a review in Critically ill patients requiring respiratory support. Levosimendan was evaluated. This position paper discusses the use of levosimendan in facilitating weaning from cardiorespiratory support in critically ill patients based on available evidence and expert opinion.
Synapse has enriched 10 related papers. Consider them for comparative context: